The Unique Pharmacological and Pharmacokinetic Profile of Teneligliptin: Implications for Clinical Practice

Overview of attention for article published in Drugs, April 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (60th percentile)
Above-average Attention Score compared to outputs of the same age and source (55th percentile)

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 12,645 followers.

RT @drakchaurasia: @OutOfTheDarkAge @Thinkerks @EbonyJHilton_MD @TheDoctors TENELIGLIPTINE - THE DPP4 ANTIDIABETIC DRUG FROM JAPAN, WHICH C…

RT @drakchaurasia: @OutOfTheDarkAge @Thinkerks @EbonyJHilton_MD @TheDoctors TENELIGLIPTINE - THE DPP4 ANTIDIABETIC DRUG FROM JAPAN, WHICH C…

RT @drakchaurasia: @OutOfTheDarkAge @Thinkerks @EbonyJHilton_MD @TheDoctors TENELIGLIPTINE - THE DPP4 ANTIDIABETIC DRUG FROM JAPAN, WHICH C…

RT @drakchaurasia: @OutOfTheDarkAge @Thinkerks @EbonyJHilton_MD @TheDoctors TENELIGLIPTINE - THE DPP4 ANTIDIABETIC DRUG FROM JAPAN, WHICH C…

RT @drakchaurasia: @OutOfTheDarkAge @Thinkerks @EbonyJHilton_MD @TheDoctors TENELIGLIPTINE - THE DPP4 ANTIDIABETIC DRUG FROM JAPAN, WHICH C…

@OutOfTheDarkAge @Thinkerks @EbonyJHilton_MD @TheDoctors TENELIGLIPTINE - THE DPP4 ANTIDIABETIC DRUG FROM JAPAN, WHICH CRASHED THE DPP4 INDUSTRY OF WEST we need a global paradigm shift in medical R&D, and information networking https://t.co/Nicq60XlZm